Optimized methods for analytical and functional comparison of biosimilar mAb drugs: A case study for Avastin, Mvasi, and Zirabev
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce
angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies …
angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies …
Similarity assessment of charge variants for bevacizumab biosimilar formulations using imaged capillary isoelectric focusing
A Bana, P Mehta - Journal of Liquid Chromatography & Related …, 2021 - Taylor & Francis
The imaged capillary isoelectric focusing method was developed and validated for charge
variant analysis of the bevacizumab innovator product and its biosimilar formulations (N= 2) …
variant analysis of the bevacizumab innovator product and its biosimilar formulations (N= 2) …
[HTML][HTML] Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab
MG Quiñonez-Alvarado, P Chávez-Hurtado… - Biologicals, 2023 - Elsevier
PRO-169 is an anti-VEGF monoclonal antibody developed by Laboratorios Sophia that
shares its sequence with Bevacizumab (BVZ); though, PRO-169 is intended for intravitreal …
shares its sequence with Bevacizumab (BVZ); though, PRO-169 is intended for intravitreal …